Mukka Proteins Limited holds 15th Annual General Meeting on 18th September 2025
The announcement describes standard proceedings of an AGM, including adopting financial statements, re-appointing directors, and appointing auditors, which are routine corporate governance matters and do not convey immediate material financial or operational changes for the company.
The announcement details the procedural aspects of the 15th Annual General Meeting, including attendance and agenda items, without revealing specific financial results or decisions that would indicate a positive or negative outlook.
Mukka Proteins Limited successfully conducted its 15th Annual General Meeting (AGM) on Thursday, 18th September 2025, at 3:00 P.M. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM). * The meeting commenced at 3:00 P.M. and concluded at 4:03 P.M. (IST). * Key attendees included the Chairman Mr. Karkala Shankar Balachandra Rao, Managing Director & CEO Mr. Kalandan Mohammed Haris, Whole Time Director & CFO Mr. Kalandan Mohammed Althaf, other Directors, Key Managerial Personnel, Statutory Auditors, and Secretarial Auditor. * A total of 74 members attended the AGM, comprising 5 from the Promoter and Promoter Group and 69 from the Public. * The agenda for the meeting included: * Receiving, considering, and adopting the Audited Standalone and Consolidated Financial Statements for the Financial Year ended 31st March 2025. * Re-appointment of Mr. Kalandan Mohammed Althaf, who retired by rotation. * Re-appointment of Mr. Kaladan Abdul Razak, who retired by rotation. * Appointment of M/s. Chethan Nayak & Associates as the Secretarial Auditors of the Company. * Alteration of the Main Object Clause of the Memorandum of Association (Special Resolution). * Shareholders were provided an opportunity to ask questions, which were addressed by the Executive Directors of the Company. * The voting results, encompassing both remote e-voting and e-voting during the AGM, will be declared upon receipt of the Scrutinizer's Report and subsequently uploaded on the company's website.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under agm-egm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.